{
    "clinical_study": {
        "@rank": "164811", 
        "arm_group": [
            {
                "arm_group_label": "SAD Cohorts 1-8 Experimental Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "SAD Cohorts 1-8 Placebo Arm", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "MAD Cohorts 3 through 5 Experimental Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MAD Cohorts 3 through 5 Placebo Arm", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "MAD Cohorts 6 and 7 Experimental Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MAD Cohorts 6 and 7 Placebo Arm", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "MAD Cohort 8 Experimental Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MAD Cohort 8 Placebo Arm", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "MAD Cohort 9 Experimental Arm", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MAD Cohort 9 Placebo Arm", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This single- and multiple-ascending dose study is the first evaluation of PF-04965842, a\n      Janus kinase1 (JAK1) inhibitor, in humans. The goal is to assess the safety, tolerability,\n      pharmacokinetics and pharmacodynamics in healthy Western and Japanese subjects."
        }, 
        "brief_title": "First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.\n\n          -  Females must be of non-child bearing potential and either at least 1 year post\n             menopausal (FSH \u226540 IU/L), or have documented hysterectomy (with or without bilateral\n             oophrectomy) at least 6 months prior to study day\n\n          -  Subjects willing to defer receiving prophylactic immunizations (e.g. influenza or\n             pneumococcal vaccines) during the study.\n\n          -  Absolute lymphocyte count must be greater than or equal to the lower limit of the\n             laboratory reference range.\n\n          -  Subjects enrolled in Cohort 8 must have four Japanese grandparents born in Japan.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, , pulmonary,\n             gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic\n             disease (including drug allergies, but excluding untreated, asymptomatic, seasonal\n             allergies at time of dosing).\n\n          -  History of hepatitis or positive testing for human immunodeficiency virus (HIV),\n             hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBc Ab) or hepatitis\n             C antibodies (HCV).\n\n          -  Clinically significant abnormality on chest X-ray performed at screening or within 3\n             months of screening date; or history of tuberculosis or active or latent or\n             inadequately treated infection."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835197", 
            "org_study_id": "B7451001"
        }, 
        "intervention": [
            {
                "arm_group_label": "SAD Cohorts 1-8 Experimental Arm", 
                "description": "Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.", 
                "intervention_name": "PF-04965842", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SAD Cohorts 1-8 Placebo Arm", 
                "description": "Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MAD Cohorts 3 through 5 Experimental Arm", 
                "description": "Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.", 
                "intervention_name": "PF-04965842", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MAD Cohorts 3 through 5 Placebo Arm", 
                "description": "Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MAD Cohorts 6 and 7 Experimental Arm", 
                "description": "Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.", 
                "intervention_name": "PF-04965842", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MAD Cohorts 6 and 7 Placebo Arm", 
                "description": "Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MAD Cohort 8 Experimental Arm", 
                "description": "Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.", 
                "intervention_name": "PF-04965842", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MAD Cohort 8 Placebo Arm", 
                "description": "Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MAD Cohort 9 Experimental Arm", 
                "description": "Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.", 
                "intervention_name": "PF-04965842", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MAD Cohort 9 Placebo Arm", 
                "description": "Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "Randomized", 
            "Double Blind", 
            "Placebo-Controlled", 
            "Single- & Multiple Dose Escalation", 
            "Safety", 
            "Tolerability", 
            "PK", 
            "PD", 
            "Pf-04965842"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7451001&StudyName=First-in-Human%20Study%20to%20Evaluate%20Safety%20and%20Tolerability%20of%20Single%20and%20Multiple%20Ascending%20Doses%20of%20Janus%20Kinase-1%20Inhibitor%20PF-04965842%20in"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "10", 
        "official_title": "A Phase 1, Within Cohort, Randomized, Double Blind, Third-Party Open, Placebo-Controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-04965842 In Healthy Western and Japanese Subjects", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Changes from baseline vital signs (blood pressure, pulse rate, oral temperature and respiration rate) and physical examinations", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Quantitative changes in ECG intervals", 
                "measure": "Changes from baseline in 12 lead ECG parameters", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Incidence and severity of treatment emergent adverse events and withdrawals due to treatment emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Incidence and magnitude of treatment emergent clinical laboratory abnormalities including hematology (with white blood cell count differentials, platelets, PT and aPTT), chemistry, fasting glucose, urinalysis", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Quantitative IgG, IgA, IgM, and IgE levels", 
                "measure": "Change from baseline in immunoglobulin levels", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "24-hour urine creatinine clearance (Single Ascending Dose Period)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Day 1"
            }, 
            {
                "measure": "24-hour urine creatinine clearance (Multiple Ascending Dose Period)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Day 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835197"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Complement Level: C3", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Complement Level: C4", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Cohorts 1-7 and Cohort 9", 
                "measure": "Complement Level: C3A", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Cohorts 1-7 and Cohort 9", 
                "measure": "Complement Level: Bb", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Single Ascending Dose: Dose-normalized Area Under the Curve From Time Zero to Infinity (AUCinf(dn))", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Multiple Ascending Dose: Accumulation Ratio based on Cmax (Rac(Cmax))", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Urinary Pharmacokinetics; for twice-a-day dosing, amount of PF-0496842 excreted unchanged in 12 hours (AE12)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Urinary Pharmacokinetics; for twice-a-day dosing, percent of PF-0496842 excreted unchanged in 12 hours (AE12%)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Vz/F is the distribution of a drug between plasma and the rest of the body following oral adminstration.", 
                "measure": "Multiple Ascending Dose: Apparent Volume of Distribution at Steady State (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Multiple Ascending Dose: Apparent Total Body Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Urinary Pharmacokinetics; for once-a-day dosing, amount of PF-0496842 excreted unchanged in 24 hours (AE24)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Urinary Pharmacokinetics; for once-a-day dosing, percent of PF-0496842 excreted unchanged in 24 hours (AE24%)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Renal Clearance (CLr)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "High-Sensitivity C-Reactive Protein (hsCRP)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Neutrophil counts", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Reticulocyte counts", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Complement Level: CH50", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Single Ascending Dose: Apparent Total Body Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Multiple Ascending Dose: Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Multiple Ascending Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Multiple Ascending Dose: Dose-normalized Maximum Observed Plasma Concentration (Cmax(dn))", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Multiple Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau(dn))", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Multiple Ascending Dose: Accumulation Ratio based on AUC predicted (Rss)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Multiple Ascending Dose: Accumulation Ration based on AUC observed (Rac)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one-half.", 
                "measure": "Multiple Ascending Dose: Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Multiple Ascending Dose: Peak to Trough Fluctuation (PTF)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Single Ascending Dose: Dose-normalized Area Under the Curve to the end of the dosing period (AUCtau(dn))", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Single Ascending Dose: Area Under the Curve From Time Zero to Infinity (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Single Ascending Dose: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Single Ascending Dose: Dose-normalized Maximum Observed Plasma Concentration (Cmax(dn))", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Single Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "Dose-normalized area under the plasma concentration time-curve from zero to the last measured concentration (AUClast(dn))", 
                "measure": "Single Ascending Dose: Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast(dn))", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Single Ascending Dose: Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Multiple Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Single Ascending Dose: Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }, 
            {
                "measure": "Single Ascending Dose: Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "8 days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}